ShockWave Medical, Inc. (SWAV): Price and Financial Metrics
GET POWR RATINGS... FREE!
SWAV POWR Grades
- Growth is the dimension where SWAV ranks best; there it ranks ahead of 94.15% of US stocks.
- The strongest trend for SWAV is in Momentum, which has been heading up over the past 177 days.
- SWAV's current lowest rank is in the Stability metric (where it is better than 6% of US stocks).
SWAV Stock Summary
- Price to trailing twelve month operating cash flow for SWAV is currently 81.68, higher than 95.18% of US stocks with positive operating cash flow.
- Over the past twelve months, SWAV has reported earnings growth of -346.83%, putting it ahead of only 4.55% of US stocks in our set.
- As for revenue growth, note that SWAV's revenue has grown 144.7% over the past 12 months; that beats the revenue growth of 94.35% of US companies in our set.
- Stocks that are quantitatively similar to SWAV, based on their financial statements, market capitalization, and price volatility, are NICE, DV, YELP, CRCT, and SPSC.
- SWAV's SEC filings can be seen here. And to visit SHOCKWAVE MEDICAL INC's official web site, go to www.shockwavemedical.com.
SWAV Valuation Summary
- In comparison to the median Healthcare stock, SWAV's EV/EBIT ratio is 621.21% higher, now standing at 71.4.
- SWAV's price/sales ratio has moved down 48.5 over the prior 47 months.
Below are key valuation metrics over time for SWAV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SWAV | 2023-01-20 | 15.2 | 18.4 | 74.2 | 71.4 |
| SWAV | 2023-01-19 | 14.7 | 17.8 | 72.0 | 69.3 |
| SWAV | 2023-01-18 | 15.2 | 18.4 | 74.3 | 71.5 |
| SWAV | 2023-01-17 | 16.2 | 19.5 | 79.0 | 76.1 |
| SWAV | 2023-01-13 | 17.0 | 20.5 | 82.9 | 79.9 |
| SWAV | 2023-01-12 | 16.8 | 20.3 | 82.2 | 79.2 |
SWAV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SWAV has a Quality Grade of D, ranking ahead of 16.69% of graded US stocks.
- SWAV's asset turnover comes in at 0.474 -- ranking 102nd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows SWAV's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.474 | 0.773 | -0.306 |
| 2021-03-31 | 0.305 | 0.725 | -0.488 |
| 2020-12-31 | 0.256 | 0.690 | -0.552 |
| 2020-09-30 | 0.233 | 0.662 | -0.751 |
| 2020-06-30 | 0.233 | 0.625 | -0.695 |
| 2020-03-31 | 0.276 | 0.612 | -0.565 |
SWAV Price Target
For more insight on analysts targets of SWAV, see our SWAV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $210.67 | Average Broker Recommendation | 1.64 (Moderate Buy) |
SWAV Stock Price Chart Interactive Chart >
SWAV Price/Volume Stats
| Current price | $187.83 | 52-week high | $320.54 |
| Prev. close | $194.64 | 52-week low | $113.36 |
| Day low | $185.59 | Volume | 231,000 |
| Day high | $193.67 | Avg. volume | 489,522 |
| 50-day MA | $218.33 | Dividend yield | N/A |
| 200-day MA | $225.76 | Market Cap | 6.79B |
ShockWave Medical, Inc. (SWAV) Company Bio
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.
Latest SWAV News From Around the Web
Below are the latest news stories about SHOCKWAVE MEDICAL INC that investors may wish to consider to help them evaluate SWAV as an investment opportunity.
How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesFinding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaBy Davit Kirakosyan |
3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses. |
ShockWave Medical (SWAV) Posts Solid Preliminary Q4 RevenuesShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business. |
SWAV stock defended at BofA; says Neovasc “not a big risk” (NASDAQ:SWAV)Bank of America reaffirmed its Buy rating on ShockWave Medical (SWAV) after its shares witnessed a sharp in reaction to a deal to acquire Neovasc (NVCN). Read the full story here. |
SWAV Price Returns
| 1-mo | -9.48% |
| 3-mo | -34.02% |
| 6-mo | -11.82% |
| 1-year | 40.31% |
| 3-year | 328.15% |
| 5-year | N/A |
| YTD | -8.65% |
| 2022 | 15.30% |
| 2021 | 71.93% |
| 2020 | 136.16% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...